Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Jack W. Singer, Angela Fleischman, Suliman Al-Fayoumi, John O. Mascarenhas, Qiang Yu, Anupriya Agarwal

Research output: Contribution to journalReview articlepeer-review

101 Scopus citations


Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

Original languageEnglish
Pages (from-to)33416-33439
Number of pages24
Issue number70
StatePublished - 1 Sep 2018


  • Cancer
  • Inflammatory diseases
  • Interleukin-1 receptor associated kinase (IRAK1)
  • MyD88
  • Pacritinib


Dive into the research topics of 'Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy'. Together they form a unique fingerprint.

Cite this